Oral
Ponatinib
Iclusig
Used only if resistance to all other agents, or if T315I mutation
- Mechanism of Action
- Inhibit the Bcr-Abl tyrosine kinase as well as the stem cell receptor factor (cKIT) and several other receptor tyrosine kinases.
Clinical Use
- Indication
- Chronic myeloid leukaemia with resistance or intolerance to at least two other tyrosine kinase inhibitors, other with T315I mutation
- Adverse Effects
- Rash
- Fatigue
- Oedema
- Nausea / vomiting / diarrhoea
- Muscle cramping
- Peripheral neuropathy
- LFT derangement
- Myelosuppression - anaemia, neutropaenia, thrombocytopaenia
- Cardiovascular - cardiac ischaemia, stroke, peripheral vascular disease, hypercholesterolaemia
Want more info like this?
- Your electronic clinical medicine handbook
- Guides to help pass your exams
- Tools every medical student needs
- Quick diagrams to have the answers, fast
- Quizzes to test your knowledge
Explore